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Comment on: Tumour necrosis factor inhibitor
survival and predictors of response in axial
spondyloarthritis—findings from a United
Kingdom cohort: reply
SIR, We thank Al Arashi et al. [1] for their interest and
comments on our recent report on tumour necrosis fac-
tor inhibitor (TNFi) survival and predictors of response in
axial spondyloarthritis—findings from a United Kingdom
cohort [2].
We did not focus specifically on sex differences in our
analysis but have now undertaken further analyses on
sex differences in our study population. We found a
higher prevalence of acute anterior uveitis (44.9 vs
33.9%, P¼0.03) and family history of SpA (45.2 vs
30.4%, P¼ 0.02) in females, but not for IBD (females
16.8% vs males 11.9%, P¼0.19) or psoriasis (females
24.3% vs males 19.5%, P¼ 0.29). This is similar to pre-
vious studies, which reported that women are more af-
fected by uveitis in SpA [3] and AS [4].
In our cohort, BASDAI50 response 3–6 months after
initiation of index TNFi was achieved by 56 (58.3%)
females and 219 (61.5%) males (P¼0.64).
Discontinuation rates for index TNFi were higher in
females (females n¼56, 37.3%; males n¼ 168, 33.5%).
In addition, females had higher rates of adverse events
(44.6 vs 33.9%), and males had a slightly higher propor-
tion of primary non-response (15.5 vs 14.3%) and sec-
ondary non-response (20.8 vs 16.1%). None of these
differences reached statistical significance.
In conclusion, there are differences between our co-
hort and those reported by Al Arashi et al. [1]; however,
sample sizes are small. Larger prospective studies are
required to evaluate sex differences in axSpA.
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